NON-SEGMENTAL VITILIGONING OG‘IRLIK DARAJASI (MILD/MODERATE VA SEVERE) VA IMMUNOLOGIK PROFIL (Th1/Th17, Treg, IL-17, IL-15) O‘RTASIDAGI BOG‘LIQLIK
Keywords:
non-segmental vitiligo, Th1, Th17, Treg, IL-17, IL-15, autoimmunitet, cytokine profile, severe vitiligo.Abstract
Non-segmental vitiligo (NSV) autoimmun mexanizmlar bilan bog‘liq bo‘lgan surunkali depigmentatsion kasallik hisoblanadi. So‘nggi yillarda Th1/Th17 yo‘li, Treg hujayralarining disfunksiyasi hamda IL-17, IL-15, IFN-γ, CXCL10 kabi sitokinlarning roli keng o‘rganilmoqda. Ushbu maqolada NSVning klinik og‘irlik darajasi (mild/moderate va severe shakllari) bilan immunologik profil o‘rtasidagi bog‘liqlik tizimli ravishda tahlil qilindi. Tadqiqot konsepsiyasi sifatida immunologik biomarkerlarning kasallik faolligi, depigmentatsiya maydoni va progressiya tezligi bilan korrelyatsiyasi baholandi. Severe NSVda Th1/Th17 aktivatsiyasi kuchayishi, IL-17 va IL-15 miqdorining yuqoriligi, Treg hujayralarining pasayishi kuzatilishi mumkinligi ilmiy asoslandi. Shuningdek, IL-15 asosidagi resident memory T-cell mexanizmi vitiligoda relapslarning asosiy omillaridan biri sifatida ko‘rib chiqildi.
References
Ezzedine K., Eleftheriadou V., Whitton M., van Geel N. Vitiligo // The Lancet. – 2015;386(9988):74–84.
Frisoli M.L., Essien K., Harris J.E. Vitiligo: Mechanisms of Pathogenesis and Treatment // Annual Review of Immunology. – 2020.
Richmond J.M., Harris J.E. Immunology and Skin in Health and Disease: Vitiligo // Cold Spring Harbor Perspectives in Medicine. – 2018.
Rashighi M., Harris J.E. Interfering with the IFN-γ/CXCL10 pathway to develop new targeted treatments for vitiligo // Annals of Translational Medicine. – 2015.
Boniface K., Seneschal J., Picardo M., Taïeb A. Vitiligo: Focus on Clinical Aspects, Immunopathogenesis, and Therapy // Clinical Reviews in Allergy & Immunology. – 2018.
Speeckaert R., van Geel N. The role of interleukins in vitiligo: a systematic review // Journal of the European Academy of Dermatology and Venereology. – 2018.
Harris J.E. Chemical-Induced Vitiligo // Dermatologic Clinics. – 2017.
Riding R.L., Harris J.E. The Role of Memory CD8+ T Cells in Vitiligo // Journal of Immunology. – 2019.
Su X., Liu F. Targeting the IL-15/CD122 signaling pathway: reversing TRM cell-mediated immune memory in vitiligo // Frontiers in Immunology. – 2025.
Paganelli A., Cristofoletti C., Moro F. et al. Comprehensive Overview of Cytokine Interplay in Vitiligo // Life. – 2025;15(5):684.
Lerner G., Nikolaou M., Stoffel C. et al. Regulatory T Cell Dysregulation in Vitiligo // International Journal of Dermatology. – 2025.
Taïeb A., Picardo M. Vitiligo // New England Journal of Medicine. – 2009.
Picardo M., Dell’Anna M.L., Ezzedine K. et al. Vitiligo // Nature Reviews Disease Primers. 2015.
Zhou L., Li K., Shi Y.L. et al. Systemic analyses of immunophenotypes of peripheral T cells in non-segmental vitiligo // International Immunopharmacology. – 2019.
Wang X.X., Wang Q.Q., Wu J.Q. et al. Increased expression of IL-17 in patients with vitiligo // Clinical and Experimental Dermatology. – 2011.
Bassiouny D.A., Shaker O. Role of interleukin-17 in the pathogenesis of vitiligo // Clinical and Experimental Dermatology. – 2011.
Lili Y., Yi W., Ji Y. et al. Global activation of CD8+ cytotoxic T lymphocytes correlates with an impairment in regulatory T cells in patients with generalized vitiligo // PLoS One. – 2012.
Dwivedi M., Kemp E.H., Laddha N.C. et al. Regulatory T cells in vitiligo: implications for pathogenesis and therapeutics // Autoimmunity Reviews. – 2015.
Rashighi M., Agarwal P., Richmond J.M. et al. CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo // Science Translational Medicine.2014.
Abdallah M., Lotfi R., Othman W., Galal R. Assessment of tissue FoxP3+, CD4+ and CD8+ T-cells in active and stable nonsegmental vitiligo // International Journal of Dermatology. – 2014.
